Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

Prior treatment

• History of immunosuppressive, chemotherapeutic, or radiation treatment within 12 months prior to Screening
• History of Type 1 diabetes or active Type 2 diabetes (T2D). If there was a history of T2D and it resolved, then the resolution must have occurred \>12 months prior to Screening. Prediabetes managed with nonpharmacologic approaches (exercise and diet) is not an exclusion

Other illness

• History of or active cardiovascular, neurovascular, peripheral vascular, pulmonary, hepatic, pancreatic, neuromuscular, and/or psychiatric disease
• Active malignancy, other than local subcutaneous squamous cell and basal cell carcinomas

• Able to comprehend the informed consent process and provide written informed consent prior to study enrollment and the conduct of any study-related assessments to study enrollment and the conduct of any study-related assessments
• Male or female, age ≥ 18 and ≤ 65 years at the time of informed consent
• Stable body weight (±5 kg) within 90 days of Screening
• At Screening, a BMI of:
  • ≥30.0 kg/m2 to ≤45.0 kg/m2 or
  • ≥27.0 kg/m2 to \<30.0 kg/m2 with the presence of 1 or more weight-related comorbid condition(s). Note: See exclusion criteria for specific organ class disease parameters